
1. gastroenterol nurs. 2015 sep-oct;38(5):369-78. doi: 10.1097/sga.0000000000000166.

project p.e.a.c.h. (pathway education toward adherence completion in
hepatitis c therapy): nurse-driven evidence-based protocol.

redulla rr(1), reddy kr, faust tw, dudley-brown s.

author information: 
(1)rhoda r. redulla, dnp, rn, director education, memorial hospital of
salem county, new jersey; adjunct faculty, drexel university, philadelphia,
pennsylvania. dr. redulla also sgna scholar. k. rajender reddy, md, ruimy
family president's distinguished professor, director hepatology, medical
director liver transplantation, hospital university pennsylvania,
philadelphia. thomas w. faust, md, mbe, transplant hepatologist, medstar
georgetown transplant institute, medstar georgetown university hospital,
washington, dc. sharon dudley-brown, phd, fnp-bc, faan, assistant professor of
medicine, johns hopkins university, baltimore, maryland. dr. dudley-brown also
a sgna scholar.

chronic hepatitis c virus (hcv) remains major healthcare concern. 24-48
week treatment pegylated interferon ribavirin therapy requires a
tremendous amount commitment patients providers. thus, been
a huge focus health-related quality life various measures support
patient adherence completion recommended hcv treatment regimen. this
quality improvement project aimed develop test nurse-driven
evidence-based pathway supports care patients receiving hepatitis c
medication therapy tertiary, academic hepatology practice. adult
patients, 18 years older, started hcv treatment january 20
to february 15, 2011, included testing nurse-driven hcv pathway 
for first 12 weeks treatment. majority patients treated were
male (71.8% prepathway 83.3% postpathway), white ethnic background (61.5% 
prepathway 58.3% postpathway), genotype 1 (69% prepathway 91.7%
postpathway), comorbid conditions classified "other" (38.5% prepathway
and 33.3% postpathway). treatment status, majority patients
were "treatment naive" prepathway never received prior hcv treatment
(59.0%) "had recurrent hcv liver transplantation" (41.7%). 4-week
treatment completion rate 94.9% prepathway group 100.0% the
postpathway group; 12-week completion rate 87.2% (prepathway) 58.3% for
the postpathway group. mean 4-week adherence score prepathway group
was 2.46 postpathway group 2.92. mean lag time treatment was
decreased 26 days postpathway 43 prepathway. providers and
nurses expressed overall satisfaction nurse-driven pathway.

doi: 10.1097/sga.0000000000000166 
pmid: 26422271  [indexed medline]

